- Trevi Therapeutics (TRVI, Financial) to present topline results from Phase 2b CORAL trial of Haduvio on June 2, 2025.
- The webcast will provide insights into Haduvio, an investigational therapy for chronic cough in IPF patients.
- Replay of the conference will be available for 30 days on Trevi’s website.
Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company, has announced that it will host a conference call and webcast on June 2, 2025, at 8:30 a.m. ET. This event aims to share the topline results from the Phase 2b CORAL trial of Haduvio, an oral extended-release nalbuphine, which is being developed for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
The conference will be accessible via webcast, complete with audio and presentation slides, ensuring a comprehensive review of the trial results. Participants can join the live conference call by dialing (877) 870 4263 for domestic callers or (412) 317 0790 for international participants. No access code is required to join the call.
For those unable to attend the live session, an archived replay of the webcast will be made available on Trevi Therapeutics’ website, remaining accessible for 30 days post-event. This initiative highlights the company’s ongoing commitment to developing effective treatments for chronic coughs, providing a potential solution for the significant number of patients affected by IPF-related chronic cough.
Chronic cough in IPF patients affects up to 85% of the population, with approximately 140,000 individuals in the U.S. alone, potentially leading to worsening disease and a decline in the quality of life. Currently, there are no approved therapies for this condition, underscoring the importance of Trevi's research efforts.
For more details, please visit Trevi Therapeutics’ official website, and follow their updates on social media platforms such as X (formerly Twitter) and LinkedIn.
